Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
October 17, 2023 07:00 ET
|
Apellis Pharmaceuticals, Inc.
In as early as 12 weeks: 80% of patients treated with pegcetacoplan showed a reduction in C3c staining by one or more orders of magnitude of intensity from baseline40% of patients showed zero staining...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2023 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
October 05, 2023 07:00 ET
|
Apellis Pharmaceuticals, Inc.
Continued strong demand, with more than 100,000 vials (commercial and sample) distributed to date; growth in week-over-week demand returned starting in AugustPermanent J-code effective as of October...
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
October 02, 2023 07:00 ET
|
Apellis Pharmaceuticals, Inc.
Compact, single-use, on-body injector designed to enhance the patient experience of administering EMPAVELI® (pegcetacoplan) WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Apellis...
Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023
September 25, 2023 07:30 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2023 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company...
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
September 05, 2023 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
August 30, 2023 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success
August 29, 2023 06:58 ET
|
Apellis Pharmaceuticals, Inc.
Maximizing global leadership of SYFOVRE in geographic atrophy (GA) Streamlining the EMPAVELI business and prioritizing development of systemic pegcetacoplan in IC-MPGN/C3G Focusing research...
Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)
August 22, 2023 16:43 ET
|
Apellis Pharmaceuticals, Inc.
Internal structural variations were identified in the 19-gauge filter needle included in certain injection kits; Apellis recommends use of kits with the 18-gauge filter needle, which are already in...